Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to comprehend and willingness to sign a written ICF for the study.~2. Male or non-pregnant females, ≥18 years of age at the time of enrolment.~3. Understands and agrees to comply with planned study procedures.~4. Agrees to the collection of pharyngeal swabs and blood sample as per protocol.~5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen within one week~6. Patients with SpO2 \> 93% and respiratory rate \<30 breaths/min.~7. Illness of any duration, and at least one of the following:~   1. Radiographic infiltrates by imaging (chest x-ray)~  2. Clinical assessment (evidence of rales/crackles or other clinical symptoms on exam).~8. Women of childbearing potential must agree to use at least one primary form of contraception~Exclusion Criteria:~1. ALT/AST \>5 times the upper limit of normal.~2. Patients with respiratory rate \<20 breaths/min and normal SpO2 with confirmed SARS-CoV-2 infection as determined by PCR (Mild COVID-19 subjects).~3. Patients with respiratory rate ≥30 breaths/min and SpO2 at rest ≤93% (Severe COVID-19 subjects).~4. Stage ≥4 severe chronic kidney disease or requiring dialysis (i.e. eGFR \<30 mL/min/1.73 m2).~5. Pregnant or breast feeding.~6. Allergy to any study medication or usage of test drug during last 14 days prior to screening~7. Severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled DM, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigator's assessment.~8. Comorbid condition like myocardial infarction or heart failure within 90 days of recruitment.~9. Prolong QT interval (\>450 ms).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pegylated Interferon-α2b + Standard of care (Type: EXPERIMENTAL): Test :- Pegylated Interferon-α2b + Standard of care (SOC)~Pegylated Interferon-α2b-Initial 1 mcg/kg will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered along with the recommended standard of care at the time of conduct of trial.
- Standard of Care (Type: ACTIVE_COMPARATOR): Control: Standard of care~Standard of care treatment will be provided as per regulatory recommendation and approval.

Based on this trial design, predict the completion outcome and termination type (if applicable).